Cost-effectiveness doubts could hit Shire’s Takhzyro launch

Vertex’s cystic fibrosis therapies can step aside – there are some new contenders for the dubious honour of being the least cost-effective drug. An analysis by the US Institute for Clinical and Economic Review (Icer) has concluded that Shire’s hereditary angioedema drugs Cinryze and Takhzyro are among the priciest it has ever evaluated.